Chronic oral methylene blue treatment in a rat model of focal cerebral ischemia/reperfusion

Lei Huang, Jianfei Lu, Bianca Cerqueira, Yichu Liu, Zhao Jiang, Timothy Q. Duong

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


A single acute low-dose methylene blue (MB), an FDA-grandfathered drug, has been shown to ameliorate behavioral deficits and reduces MRI-defined infarct volume in experimental ischemic stroke when administered intravenously or intraperitoneally. The efficacy of chronic MB treatment in ischemic stroke remains unknown. In a randomized, double-blinded and vehicle-controlled design, we investigated the efficacy of chronic oral MB administration in ischemic stroke longitudinally up to 60 days post injury using MRI and behavioral tests, with end-point histology. The major findings were chronic oral MB treatment, compared to vehicle, i) improves functional behavioral outcomes starting on day 7 and up to 60 days, ii) reduces MRI-defined total lesion volumes from day 14 and up to 60 days where some initial abnormal MRI-defined core and perfusion-diffusion mismatch were salvaged, iii) reduces white-matter damage, iv) gray matter and white matter damages are consistent with Nissl stains and Black Gold stain histology. These findings provide further evidence that long-term oral administration of low-dose MB is safe and has positive therapeutic effects in chronic ischemic stroke.

Original languageEnglish (US)
Pages (from-to)322-329
Number of pages8
JournalBrain research
StatePublished - Jan 1 2018
Externally publishedYes


  • Chronic stroke
  • Lesion volume
  • MRI
  • Methylene blue
  • White matter injury

ASJC Scopus subject areas

  • General Neuroscience
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology


Dive into the research topics of 'Chronic oral methylene blue treatment in a rat model of focal cerebral ischemia/reperfusion'. Together they form a unique fingerprint.

Cite this